IP Library Granted Patent US 10,183,006
Granted Patent B2
US 10,183,006 · App. 15/980,376 · Granted Jan 22, 2019

Methods of therapeutic monitoring of nitrogen scavenging drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,183,006
App. No.
15/980,376
Granted
Jan 22, 2019
Kind
B2
Abstract

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Claims (9)

1. A method of treating a urea cycle disorder (UCD) in a subject in need thereof who has hepatic impairment wherein the hepatic impairment is of class B or C according to the Child-Pugh Score, the method comprising:

administering a nitrogen scavenging agent to the subject at a dosage of 5 g/m 2 /day,

wherein the nitrogen scavenging agent is glyceryl tri-[4-phenylbutyrate].

2. The method of claim 1 , further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on a target nitrogen output.

3. The method of claim 1 , further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on urinary PAGN level.

4. The method of claim 1 , further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on the subject's urinary PAGN level in combination with the subject's ammonia level.

5. The method of claim 1 , further comprising administering an increased dosage of the nitrogen scavenging agent to the subject wherein the increased dosage is calculated based on the ratio of the concentration of urinary PAGN to urinary creatinine.

6. The method of claim 1 , further comprising administering an increased dosage of the nitrogen scavenging agent to the subject, if the subject's fasting blood ammonia level is greater than half the upper limit of normal for the laboratory which performed the fasting blood ammonia level measurement.

7. The method of claim 1 , wherein the nitrogen scavenging agent is administered orally.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0075 →
SECURITY AGREEMENT Recorded Oct 24, 2018
From: HORIZON PHARMA RHEUMATOLOGY LLC; HZNP LIMITED; HORIZON THERAPEUTICS, LLC
To: CITIBANK, N.A.
Reel/Frame 047720/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2018
From: SCHARSCHMIDT, BRUCE F.
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 046043/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2018
From: MOKHTARANI, MASOUD
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 046043/0725 →
CHANGE OF NAME Recorded Jun 11, 2018
From: HORIZON THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 046333/0986 →